心血管疾病（CVD）患者是感染新型冠状病毒肺炎（COVID⁃19）的高危人群，合并CVD的CO⁃VID⁃19患者危重症比例和病死率明显升高。目前针对新型冠状病毒（SARS⁃CoV⁃2）感染尚无特异抗病毒药物，2020 年8 月，国家卫生健康委员会发布了《新型冠状病毒肺炎诊疗方案（试行第八版）》，推荐治疗COVID⁃19 的主要抗病毒药物有α⁃干扰素、利巴韦林、磷酸氯喹、阿比多尔和洛匹那韦/利托那韦。抗病毒药物对心血管系统有一定的不良影响，本文结合治疗COVID⁃19 的抗病毒药物与心血管药物的相互作用和不良反应，提出合理的用药监护建议，旨在为COVID⁃19合并心血管疾病患者的临床药物选择和用药管理提供科学依据和参考。

Patients with cardiovascular disease （CVD） are at high risk of coronavirus disease 2019（COVID⁃19）and the mortality of COVID⁃19 patients with CVD were significantly increased.Currently，there is noevidence that any antiviral drugs were effective to severe acute respiratory syndrome coronavirus 2（SARS⁃CoV⁃2）.In August，2020，National Health Commission issued Diagnosis and Treatment Protocol for COVID⁃19（Trial Version8）and the main antiviral drugs recommended for the treatment of COVID⁃19 are IFN⁃α，Ribavirin，Chloroquinephosphate，Arbidol，Lopinavir/ritonavir（LPV/r）and so on. All of these drugs have some adverse effects on cardio⁃vascular system. The review summarizes pharmaceutical care strategy for COVID⁃19 patients with cardiovasculardisease，and aims to provide useful guidance for pharmaceutical management and treatment of COVID⁃19 patientswith CVD.